Xeris Biopharma Holdings (NASDAQ:XERS) CEO Paul Edick tells Proactive’s Stephen Gunnion that results from a Phase 1 study of subcutaneous (SC) levothyroxine (XP-8121) offer initial proof of concept that its novel formulation has the potential to provide patients with a once-weekly dosing of the drug.
Edick explains that the formulation, developed using its XeriSol technology, may improve treatment adherence, while bypassing the gastrointestinal tract and mitigating limitations of oral therapy.
#ProactiveInvestors #XerisBiopharma #levothyroxine #XP-8121 #Nasdaq
